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Um procedimento simples, rápido e de baixo custo é descrito para a determinação de captopril 
em preparações farmacêuticas. O procedimento é baseado em um sistema de análises por injeção 
em fluxo explorando a formação em linha de triiodeto, o qual é consumido na presença do 
analito gerando um sinal transiente. Resposta linear foi observada até 200 µmol L-1 com limite de 
detecção de 1,0 µmol L-1 (99,7% de confiança). O coeficiente de variação (n = 20) e a freqüência de 
amostragem foram estimados em 1,2% e 72 determinações por hora, respectivamente. Os principais 
excipientes encontrados em preparações farmacêuticas não afetaram a determinação de captopril. 
Reamostragem na zona dispersa foi explorada para implementar diluições em linha, visando a 
análise direta de suspensões das amostras. Resultados da análise de amostras comerciais foram 
concordantes com os obtidos pelo procedimento volumétrico de referência descrito na Farmacopéia 
americana com nível de confiança de 95%. O consumo de reagente foi estimado em 18 µg KMnO4 
e 10 mg KI por determinação, com custo de US$ 2,50 por 1000 determinações.
A simple, fast and low cost procedure for spectrophotometric determination of captopril in 
pharmaceutical preparations is described. The procedure is based on a flow-injection system 
exploiting the on-line formation of the triiodide reagent, which is consumed in the presence of 
the analyte generating a transient signal. Linear response was observed up to 200 µmol L-1 with a 
detection limit of 1.0 µmol L-1 (99.7% confidence level). The coefficient of variation (n = 20) and 
the sampling rate were estimated as 1.2% and 72 determinations per hour, respectively. The main 
excipients found in pharmaceutical preparations did not affect the captopril determination. The 
zone sampling approach was exploited to implement on-line dilutions, aiming direct analysis of 
sample extracts. Results of the analysis of commercial samples agreed with the obtained by the 
titrimetric reference procedure described in the US-Pharmacopeia at the 95% confidence level. 
The reagent consumption was estimated as 18 µg of KMnO4 and 10 mg of KI per determination, 
with a cost of US$ 2.50 per 1000 determinations.
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Introduction
Arterial hypertension is one of the diseases with major 
prevalence in the world, being estimated that one in six 
habitants is affected by this health problem. Although 
caused by still unknown factors, some risk factors contribute 
to the development of this pathology, like family history, 
age, high salt intake, obesity, sedentariness, alcoholism and 
stress.1 In Brazil, it is estimated that 15 to 20% of adult 
population is affected by this disorder.2
The first drug planned to be used for arterial 
hypertension treatment was captopril, 1-[(2S)-3-mercapto-
2-methylpropionyl]-L-proline (Figure 1), which belongs 
to the class of angiotensin-converting enzyme (ACE) 
inhibitors. This drug interacts with ACE due to its similarity 
with a dipeptide and the sulphydryl group also plays an 
important role, linking covalently to the zinc atom in 
the enzyme active site. This drug is widely used mainly 
for arterial hypertension treatment, but also in diabetic 
nephropathy and congestive cardiac insufficiency.3-5
Captopril determination in pharmaceuticals is usually 
performed by volumetry or high performance liquid 
Figure 1. Molecular structure of captopril.
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chromatography (HPLC), as described in the United States 
Pharmacopeia.6 The volumetric procedure is based on captopril 
titration in acid medium using an iodine solution in presence 
of excess of iodide, with starch as indicator. Although precise 
and exact, the procedure is time-consuming. HPLC procedures 
need expensive and complex equipment, also consuming 
significant amounts of solvents. These drawbacks hinder the 
use of these procedures for routine analysis. 
Flow injection systems have been employed specially 
for mechanization of analytical procedures, in order to 
minimize the analyst intervention, enhancing the number 
of samples processed by time and improving precision. 
These systems also show a great potential for development 
of greener analytical procedures, with reduced waste 
production when compared to the batch ones.7,8
Some f low-based procedures  for  captopri l 
determination were presented, exploiting detection 
by spectrophotometry,9-13 chemiluminescence14-21 or 
biamperometry.22 These procedures use heavy metals,9 
reagents hazardous to the environment10 or present 
problems related to precision15 and sensitivity.12
In this work, it is described a flow-based analytical 
procedure for captopril determination with spectrophotometric 
detection based on the consumption of triiodide. The zone 
sampling strategy23 was exploited for on-line dilutions, 
aiming the direct analysis of extracts of pharmaceutical 
preparations. 
Experimental
Apparatus
The flow systems were constructed with sliding-
bar injectors, 0.7 mm i.d. polyethylene tubes and 
Perspex joint points. An injector with electronic 
time-control (Micronal) was used for on-line sample 
dilution. An Ismatec IPC-8 peristaltic pump equipped 
with Tygon tubes was used for fluid propelling. An 
UV-Vis spectrophotometer (Hitachi, U-3000) with a 
10 mm optical path (80 µL inner volume) quartz flow 
cell (Hellma) was employed for signal measurements. 
The spectrophotometer was interfaced to a Pentium II 
microcomputer in order to adjust instrumental parameters 
and data acquisition. 
Reagents and solutions
All solutions were prepared with analytical grade 
chemicals and distilled-deionized water. Captopril was 
supplied by Pharma Nostra (http://www.pharmanostra.com.
br/2006) and other chemicals were purchased from Merck. 
The reference solutions were prepared in the range 5.0-
200 µmol L-1 by dilution of a 5.0 mmol L-1 stock solution, 
prepared by dissolving 54.3 mg captopril in water to a 
final volume of 50 mL. The stock solution was previously 
standardized by iodimetric titration.6 
A 45 µmol L-1 potassium permanganate solution (R1) 
was daily prepared by dissolving 5.9 mg KMnO4 in 250 mL 
of 9.0 mmol L-1 sulfuric acid. A 80 mmol L-1 potassium 
iodide solution (R2) was weekly prepared by dissolving 
3.32 g of KI in 250 mL of water.
The effect of some species commonly present as 
excipients in commercial pharmaceutical preparations was 
evaluated. For compounds of low solubility in water, like 
microcrystalline cellulose, magnesium stearate, stearic 
acid and starch, suspensions were prepared from 0.1 g of 
solid in 50 mL of a solution containing a fixed amount 
of captopril (70 µmol L-1). The mixtures were shaken for 
10 min, followed by 5 minutes of centrifugation, filtration 
and analysis in the proposed flow system. The effect of the 
water soluble species (i.e. lactose, glucose and sucrose) was 
evaluated in concentrations up to 500 times higher than 
captopril, maintained as 70 µmol L-1.
Sample preparation
Samples were purchased at local drugstores. The 
pharmaceutical preparations contained as excipients 
microcrystalline cellulose, starch, lactose, magnesium stearate, 
stearic acid, sodium croscarmellose and silicon dioxide. 
Fifteen tablets of each medicine were finely powdered. For 
the procedure with manual dilution (Figure 2a), a mass ca. 
500 mg was shaken in 200 mL of deionized water for 15 min. 
The resulting mixture was filtered through a filter paper and 
the filtrate diluted with water to 250 mL. This solution was 
diluted with water to ca. 30 µmol L-1 captopril, according to the 
labeled value. For the analysis with zone sampling, a mass ca. 
200 mg was shaken in 50 mL of deionized water for 15 min. 
After centrifugation for 10 min, the supernatants were directly 
introduced in the flow system described in Figure 2b.
Flow diagram and procedure
The flow diagram of the system for captopril 
determination with previous sample dilution is presented 
in Figure 2a. In the position showed, sample (S) is aspirated 
to fill the 300 µL loop (L), while R1 and R2 are mixed at the 
joint point Y. The reaction between permanganate and iodide 
is developed through the 50 cm long coil (B1) producing 
on-line the triiodide reagent. The baseline is established in 
function of radiation absorption by the reagent mixed with 
the carrier stream. In the alternative resting position of the 
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commutator, sample is inserted into the water carrier stream 
(C), being mixed at the joint point X with the produced 
triiodide. The oxidation of captopril occurs in a 200 cm 
long coil (B2) and the analytical signal was based on the 
diminution of the absorbance at 350 nm related to the 
consumption of triiodide. The spectrophotometer software 
was employed for data acquisition and measurements were 
based on peak height and carried out in triplicate.
The flow diagram of the system for dilution by zone 
sampling23 is shown in Figure 2b. In the position showed, 
a 50 µL sample aliquot is inserted in the carrier C1, being 
dispersed at the coil DC. After a previously defined time 
interval (ts1), the injector is moved back to the alternative 
resting position and a tail portion of the dispersed sample 
zone is inserted into the carrier C2. Sample and reagent 
mixing occurs in coil B2 and measurement was carried out 
as previously described.
The procedure described in the United States 
Pharmacopeia, based on iodimetric titration,6 was used as 
reference for the analysis of commercial samples. 
Results and Discussion
General aspects
The spectrophotometric determination was based on 
consumption of triiodide (I3−) by captopril. Potassium 
permanganate in acid medium oxidizes iodide to generate 
iodine (equation 1). In excess of iodide, iodine forms the 
triiodide complex (equation 2), which absorbs at 350 nm. 
Captopril reduces triiodide to iodide (equation 3), due 
to the sulphydryl group linked to the carbonic chain 
(Figure 1). Other reagents do not absorb at the measured 
wavelength.
2 MnO4− + 10 I− + 16 H+ → 2 Mn2+ + 5 I2 + 8 H2O  (1)
I2 + I
−
 → I3−  (2)
I3
−
 + 2 C8H14O3NC-SH → 
                   3 I− + C8H14O3NC-S-S-CNO3H14C8 + 2H+  (3)
Preliminary measurements were carried out by using starch 
as indicator, added to the R2 solution. The sensitivity obtained 
with the indicator (4828 L mol-1) was similar to the attained 
without the indicator (4907 L mol-1) at the wavelengths of 
maximum absorption (580 and 350 nm, respectively), but 
linearity was better in the absence of starch (r = 0.999). 
With continuous use of the reagent containing starch, it was 
observed the impregnation of the blue-violet product in the 
tubes and flow cell, causing baseline drift (ca. 0.2 h-1). In 
addition, it was necessary to prepare the starch solution daily to 
avoid fungus growth, which hinders the indicator property. The 
utilization of starch was avoided in view of these drawbacks. 
Absorption spectra of several extracts of sample preparations 
showed that absorption occurs only for wavelengths lower 
than 240 nm. Thus, measurements at 350 nm (wavelength 
of maximum absorption of I3−) would not be affected by the 
sample components.
System optimization
The relevant hydrodynamic and chemical parameters 
were optimized by the univariate method, by considering 
the magnitude of the analytical signal, precision, reagent 
consumption and the absorbance value corresponding to 
the baseline. The ranges evaluated of each variable and the 
selected values are presented in Table 1.
Figure 2. Flow diagram of the system for captopril determination with (a) 
manual or (b) on-line sample dilution. P: Peristaltic pump; S: Sample; C, C1, 
C2: Carrier streams (water, 3.0 mL min-1); DC: 100 cm dispersion coil; B1, 
B2: 50 and 200 cm coiled reactors, respectively; R1: 45 µmol L-1 KMnO4 in 
9.0 mmol L-1 H2SO4 (3.0 mL min-1); R2: 80 mmol L-1 KI (0.9 mL min-1); L, 
L2: 300 µL and L1: 50 µL sample loops; D: Spectrophotometer (λ = 350 nm); 
X and Y: confluence joint points and W: Waste vessel.
Table 1. Optimized parameters to the proposed system
Parameter Range studied Selected value
Sample loop / µL 150-450 300
R1 flow-rate / (mL min-1) 0.9-3.0 3.0
R2 flow-rate / (mL min-1) 0.9-3.0 0.9
KMnO4 concentration / (µmol L-1) 45-150 45
KI concentration / (mmol L-1) 0.8-160 80
B1 length / cm 25-150 50
B2 length / cm 100-300 200
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The effect of concentration and flow-rate of both 
reagents are presented in Figure 3. In the former experiment 
(Figure 3I), the reagent flow-rates were kept constant (3.0 and 
1.2 mL min-1 for R1 and R2, respectively) while the reagent 
concentrations were varied. The effect of the reagent amount 
in the sample zone was then evaluated without significant 
changes in sample dispersion. The oxidant concentration 
limits the amount of I3− generated, and thus the magnitude 
of the baseline, because KI is used in excess. In the range 
15-60 µmol L-1, the oxidant concentration affected only 
slightly the analytical signal (Figure 3Ia). The permanganate 
concentration was thus fixed as 45 µmol L-1 because the 
baseline kept close to absorbance = 1.0, maximizing the linear 
range and reducing the error related to the spectrophotometric 
measurements. The effect of KI concentration was then 
evaluated (Figure 3Ib) and the analytical signal increased 
up to 80 mmol L-1. This concentration was selected for 
further studies in order to maximize the analytical response 
with minor reagent consumption. In the second experiment, 
reagent flow-rates were evaluated between 0.9 and 3.0 mL 
min-1 at the concentrations previously defined. In Figure 3II, 
similar results were obtained for both reagents, indicating 
that diminution of the analytical signal with the flow-rate 
was related to sample dilution. The KI flow-rate was then 
maintained as 0.9 mL min-1 to minimize this effect and 
reagent consumption. However, in disagreement with the 
observed when the KMnO4 flow-rate was 3.0 mL min-1, 
calibration curves were not linear (r < 0.992) when R1 reagent 
was introduced at 0.9 mL min-1, even when the concentration 
was increased to 150 µmol L-1. This observation is related to 
the higher sample dilution when the flow-rate of the confluent 
stream is increased, resulting in a higher excess of triiodide in 
relation to captopril. Thus, flow-rates of the reagents R1 and 
R2 were maintained as 3.0 and 0.9 mL min-1, respectively, 
yielding baseline absorbance values close to 1.0 and linear 
calibration curves (r > 0.999).
The length of the reactor coil B1, which affects reagent 
mixing conditions and the residence time for generation 
of triiodide, was evaluated between 25 and 150 cm. Stable 
baselines were obtained for reactor coils longer than 50 cm. 
As the analytical signal was only slightly different for the 
evaluated reactor lengths (variations lower than 7%), a 
50 cm reactor was selected for further studies. The length 
of the reactor coil B2 is an important parameter which 
affects mixing conditions and defines the residence time for 
reagent reduction by captopril, as well as sample dispersion. 
It was evaluated in a batch experiment that the reduction of 
triiodide by captopril is relatively fast, achieving the steady-
state condition after ca. 5 s. The results obtained by varying 
the coil length between 100 and 300 cm were in agreement 
with the observation that the analytical signal diminishes by 
increasing the reactor coil in view of the sample dispersion. 
Despite the analytical signal decreased 10% in relation to 
the achieved with a 100 cm long reactor, a 200 cm coil was 
selected in view of lower baseline noise. 
The effect of the sample volume was evaluated between 
150 and 450 µL. A 300 µL sample loop was selected 
because the analytical response was only 7.2% lower than 
that obtained with a 450 µL loop, while the washing time 
increased 40% for the higher sample loop, which could 
affect the sampling rate. 
Analytical features
In the optimized conditions, stable baselines and good 
precision were achieved (Figure 4) with linear response up 
to 200 µmol L-1, described by the equation ∆A = (0.02116 ± 
0.00028) + (0.00465 ± 0.00001) × C (r = 0.999), in which 
∆A is the absorbance variation at 350 nm and C is the 
captopril concentration in µmol L-1. The detection limit 
was estimated as 1.0 µmol L-1 from the standard deviation 
of 20 measurements of the blank solution, according to 
IUPAC recommendations24 at the 99.7% confidence level. 
The coefficient of variation (n = 20) and sampling rate 
were estimated as 1.2% and 72 determinations per hour, 
respectively. 
Figure 3. Effect of reagent concentration (I) and flow rate (II) on the 
analytical signal: (a) KMnO4 and (b) KI. KMnO4 and KI concentrations 
in µmol L-1 and mmol L-1, respectively. All measurements were carried 
out at 350 nm.
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The analytical features of the proposed procedure were 
comparable or superior to the obtained in others flow-
based procedures for the anti-hypertensive determination, 
as showed in Table 2.9-22 Sensitivity was 2.9 to 26-fold 
higher than the achieved in previous spectrophotometric 
procedures with measurements in the visible,9-13 
however, lower than the obtained in procedures based on 
chemiluminescence.14-21 On the other hand, selectivity is 
a critical aspect in these procedures, because the sample 
matrix has a significant effect on the chemiluminescence 
intensity.25 The linear response and coefficient of variation 
are comparable to the observed in other procedures. The 
sampling rate is quite satisfactory for routine analysis and 
low amounts of low cost reagents largely available in most 
analytical laboratories are consumed. In opposition, some 
procedures use expensive reagents9 or in large amounts (e.g. 
4.0 mol L-1 sulfuric acid16) or, still, generate toxic wastes 
containing hazardous compounds, as 1,10-phenantroline, 
hydrazone species, formaldehyde and luminol. The reagent 
consumption was estimated as 18 µg KMnO4, 10 mg KI and 
a quantity equivalent to 1.2 µL of concentrated H2SO4 per 
determination. By considering the reagent amounts, the cost 
was estimated as US$ 2.50 per 1000 determinations.
Effect of excipients
The effect of some species commonly present in 
captopril pharmaceutical formulations (lactose, glucose, 
sucrose, starch, stearic acid, magnesium stearate and 
microcrystalline cellulose) was evaluated in molar quantities 
Figure 4. Transient signals obtained for different captopril concentrations. 
The inset shows the corresponding calibration graph. Numbers indicate 
concentrations in µmol L-1.
Table 2. Comparison of analytical features of flow procedures for captopril determination
Method principle LOD /  (µmol L-1) Linear range / (µmol L-1)
Coefficient of 
variation / (%) Sampling rate / h
-1 Reference
Reaction with PdCl2 in HCl mediuma,1 2.2 20-600 0.6 90 9
Reaction with Fe(III) and complexation of Fe(II) with 
1,10-phenantrolinea,2 5.0 10-800 0.2 60 10
Inhibitory effect on formation of Co(II)-2,2’-dipyridil-2-
pyridilhydrazone in ethanol mediuma,3 12 < 1200 0.8 60 11
Reduction of Fe(III) to form Fe(II)/ 2,2’-dipyridil-2-
pyridilhydrazone complex in ethanol mediuma,1,4
32 55-4600 1.2 60
12
18 32-4600 0.8 120
Reaction with iodate in the presence of iodide, kinetic 
determinationa,5 — 46-276 — 100 13
Enhancing effect of captopril on luminol/ferrycianide 
reactionb,2 — 0.46-180 1.0 90 14
Enhancing effect of captopril on luminol/H2O2 reactionb,1 9.2 × 10-3 0.023- 23 3.1 180 15
Reaction of captopril with KMnO4 and formaldehyde in  
H2SO4 b,6
5.1 × 10-2 0.23-9.2 1.2 — 16
Complex formation with Co(II) and enhancing effect on 
oxidation of luminol by dissolved O2b,1
0.01 0.032-4.6 3.0 120 17
Reaction with permanganate and quinine-sensitized 
chemiluminescenceb,1 0.03 0.1-4.6 2.0 120 18
Reaction with electrogenerated Ag(II)b,1 0.03 0.92-46 2.7 60 19
Reaction with electrogenerated Mn(III)b,1 0.08 0.3-100 — — 20
Photochemical reaction with Ce(IV) sensitized by 
rhodamine 6Gb,1 0.2 1-200 2.8 500 21
Reaction with Fe(III) and biamperometric detection of 
Fe(II)c,1 0.05 0.14-16.6 0.97 69 22
Consumption of I3− produced on-linea,1 1.0 < 200 1.2 72 Proposed system
Detection: a, spectrophotometry; b, chemiluminescence and c, amperometry. 1, FIA/confluent streams; 2, FIA/merging zones; 3, r-FIA; 4, sequential 
injection analysis; 5, multipumping flow system; 6, stopped-flow.
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up to 500-fold superior to the analyte concentration. The 
solutions or suspensions were prepared with a fixed 
amount of captopril (70 µmol L-1) and the results were 
compared with the obtained with a solution prepared 
without the concomitants. The maximum tolerated amount 
(interference lower than 5%) is presented in Table 3, 
showing that the usual amounts in pharmaceutical 
formulations did not interfere in captopril determination 
by the proposed procedure.
Zone sampling
The zone sampling approach was evaluated to 
implement on-line sample dilution, exploiting the flow 
system in Figure 2b. With this strategy, the coefficient of 
dispersion is defined by the volume of the loops L1 and 
L2 as well as the portion of the dispersed zone inserted in 
the carrier C2 (defined by the resting time of the injector 
in the injection position, ts1). Operational conditions were 
established to implement a 50-fold sample dilution (similar 
to the batch one) with experiments carried out with colored 
solutions (potassium permanganate). The results showed 
in Figure 5a and b indicate that the required dilution is 
attained when ts1 = 19 s, for L1 = 50 µL and L2 = 300 µL. 
Under these conditions, precise sample dilution can be 
implemented (coefficient of variation = 0.9%) as showed 
in Figure 5c.
Sample analysis
Samples were processed as described on item Sample 
preparation and then analyzed by the proposed procedure 
with batch and on-line dilution, as well as by the titrimetric 
procedure described in the United States Pharmacopeia.6 
In accordance with a paired Student t-test, the results 
presented in Table 4 agreed with the obtained by the 
reference method at the 95% confidence level.
Table 3. Maximum tolerated concentrations (inference lower than 5%) 
of concomitants species in captopril determination
Species Maximum tolerated 
concentration / (g L-1)
Lactose 12.6
Glucose 6.3
Sucrose 6.0
Starch 2.0
Stearic Acid 2.0
Magnesium stearate 2.0
Microcrystalline cellulose 2.0
Table 4. Captopril determination in commercial pharmaceutical 
samples
Sample
Captopril amount / (mg per tablet)
Labeled 
value
Proposed method Volumetric 
method6manual dilution on-line dilution
1 12.5 12.81 ± 0.07 12.62 ± 0.07 12.77 ± 0.05
2 12.5 12.80 ± 0.07 11.86 ± 0.05 12.10 ± 0.29
3 12.5 13.79 ± 0.08 13.01 ± 0.10 13.12 ± 0.07
4 25 23.53 ± 0.23 27.41 ± 1.15 
5 50 51.03 ± 0.08  51.20 ± 0.24
Figure 5. Zone sampling experiment with potassium permanganate 
solutions: (a) Transient signals obtained for 0.4 mmol L-1 KMnO4 in the 
experimental conditions adopted in Figure 2a; (b) effect of ts1 (16-25 s) 
on sample dilution and (c) evaluation of repeatability for ts1 = 19 s. 
Experiments (b) and (c) were carried out with the flow system on Figure 
2b and 20 mmol L-1 KMnO4.
Conclusions
The proposed procedure is a simple, fast, greener and 
inexpensive alternative for routine analysis of captopril in 
pharmaceutical formulations, exploiting a chemistry similar 
to the used in the reference volumetric method. Analytical 
performance is comparable or better than the achieved in 
most of the flow-based procedures for determination of the 
anti-hypertensive. Common concomitants do not interfere 
even when in amounts significantly higher than the usual. The 
required reagents are commonly used in most laboratories, 
being consumed in micro-amounts and generating a low 
toxicity waste. On-line sample dilution can be implemented 
by the zone sampling approach, aiming processing directly 
the extracts of the pharmaceutical preparations.
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